Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.10 USD
Change Today +0.02 / 0.96%
Volume 27.5K
BOTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (BOTA) Key Developments

Biota Pharmaceuticals Advances RSV Program With Commencement of Dosing in Phase 1 Trial for Direct-Acting Antiviral BTA585

Biota Pharmaceuticals, Inc. announced that it has commenced dosing in a 50-subject, randomized, placebo-controlled, Phase 1 single ascending dose (SAD) trial to evaluate the safety and pharmacokinetics (PK) of BTA585 in healthy volunteers. BTA585, a potent inhibitor of viral entry into cells, is an orally bioavailable compound in clinical development for the treatment of respiratory syncytial virus (RSV) infections in children, the elderly and immunocompromised patients. The Phase 1 SAD trial has five dose level cohorts ranging from 50 mg to 500 mg. In order to evaluate the effect of food on the plasma PK of BTA585, one cohort will initially be dosed fasted then with food. Following a safety assessment of the initial dose level cohorts of the SAD trial, the Company plans to begin dosing in a Phase 1 multiple ascending dose study in the fourth quarter of 2015.

Biota Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Biota Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net income of $1.2 million, or $0.03 per share, compared to $3.2 million or $0.09 per share, for the same quarter ended March 31, 2014. Total revenue was $5.9 million, compared to $29.5 million for the same quarter ended March 31, 2014. Income from operations was $1.1 million compared with $3.2 million a year ago. Income before tax was $1.2 million compared with $3.2 million a year ago. For the nine months, the company reported net income of $0.8 million, or $0.023 earnings per share, compared to a net loss of $0.08 million, or $0.03 loss per share, for the same period ended March 31, 2014. Total revenue was $20.5 million, compared to $60.3 million for the same period ended March 31, 2014. Income from operations was $0.5 million compared with loss from operations was $1.0 million a year ago. Income before tax was $0.8 million compared with loss before tax was $0.9 million a year ago.

Biota Pharmaceuticals, Inc. to Report Q3, 2015 Results on May 07, 2015

Biota Pharmaceuticals, Inc. announced that they will report Q3, 2015 results at 9:00 AM, US Eastern Standard Time on May 07, 2015

Biota Pharmaceuticals, Inc., Q3 2015 Earnings Call, May 07, 2015

Biota Pharmaceuticals, Inc., Q3 2015 Earnings Call, May 07, 2015

Biota Pharmaceuticals, Inc. Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial

Biota Pharmaceuticals, Inc. announced that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV) infected patients with moderate-to-severe asthma from the United States and multiple European countries over the next 12 months and to report top-line data in mid-2016. The primary endpoint of this multi-center, randomized, double-blind, placebo-controlled dose-ranging study is the change from baseline to study day 14 measured by an asthma control questionnaire (ACQ)-6 total score. The secondary endpoints are focused on safety and tolerability, lung function assessments such as forced expiratory volume in one second, incidence of asthma exacerbations, assessments of the severity and duration of cold symptoms measured by the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) and virological assessments such as changes in viral load.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOTA:US $2.10 USD +0.02

BOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.263.20 CHF -3.80
View Industry Companies
 

Industry Analysis

BOTA

Industry Average

Valuation BOTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.